Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747012 | 1.00 | RIPK1 (0.49) | RIPK1TACR1OPRM1TERTHSP90AA1 | |
| SCHEMBL21494205 | 0.85 | RIPK1 (0.43) | RIPK1TACR1OPRM1HSP90AA1HSP90AB1 | |
| SCHEMBL21494206 | 0.85 | RIPK1 (0.43) | RIPK1TACR1OPRM1HSP90AA1HSP90AB1 | |
| SCHEMBL2598872 | 0.81 | RIPK1 (0.46) | RIPK1HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL15154729 | 0.81 | RIPK1 (0.46) | RIPK1HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL24993318 | 0.80 | RIPK1 (0.47) | RIPK1NTRK1 | |
| SCHEMBL28491094 | 0.78 | SCN9A (0.38) | TERTNTRK1ESR1ESR2 | |
| SCHEMBL21514000 | 0.74 | RIPK1 (0.45) | RIPK1TACR1NTRK1AGTR2 | |
| SCHEMBL24595420 | 0.74 | RIPK1 (0.45) | RIPK1TACR1NTRK1AGTR2 | |
| SCHEMBL2646291 | 0.74 | RIPK1 (0.42) | RIPK1HSP90AA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584759-B2 | Macrocyclic kinase inhibitor | HITGEN INC. (CN) | 2023-02-21 | — | — | US | disclosed |
| EP-3783000-B1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210147443-A1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3783000-A1 | MACROCYCLIC KINASE INHIBITOR | Hitgen Inc. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201282-A1 | MACROCYCLIC KINASE INHIBITOR | 成都先导药物开发股份有限公司 | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147443-A1 | MACROCYCLIC KINASE INHIBITOR | MAP3K20, TNK2, NTRK1 | RIPK1 185/4885TACR1 2811/4885OPRM1 3846/4885 |
| US-11584759-B2 | Macrocyclic kinase inhibitor | MAP3K20, TNK2, NTRK1 | RIPK1 185/4885TACR1 2811/4885OPRM1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.